Ubrogepant vs. Triptans: Superior Relief in Migraine Management

Research Summary

A recent study published in Pain Management explored real-world experiences of migraine patients switching from oral triptans to either another triptan or ubrogepant. Conducted over four weeks with 211 participants from the Migraine Buddy app, the research focused on treatment satisfaction and preference. Results showed that 69.4% of those who switched to ubrogepant reported satisfaction with pain relief and alleviating their most bothersome symptom compared to 42% in the triptan group. Additionally, 75.7% preferred ubrogepant over their prior triptan, with significant improvement in relief within two hours. The study highlights ubrogepant’s effectiveness for those switching from triptans.

Study Details

📄 Title: Patient-centered outcomes in the acute treatment of migraine: a prospective, real-world, longitudinal survey study (UNIVERSE II) comparing migraine patients who switch from a prior triptan to another triptan or ubrogepant.

👥 Research Team: Lipton RB et al.

📚 Published In: Pain Manag

📅 Publication Date: 2025 Nov 19

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.